PTJ
NGNE icon

Paul Tudor Jones’s Neurogene NGNE Stock Holding History

Paul Tudor Jones’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,246
Closed -$220K – 1819
2016
Q1 		$220K Sell
1,246
-165
-12% -$32.1K 0.01% 1461
2015
Q4 		$352K Buy
1,411
+161
+13% +$42.4K 0.01% 1136
2015
Q3 		$352K Buy
+1,250
New +$288K 0.01% 993

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.76% 1-Year Est. Return

Paul Tudor Jones's NGNE Position: Q2 2016 in Review

Paul Tudor Jones sold out of Neurogene (NGNE) in Q2 2016, closing a stake of 1,246 shares — an estimated $220K sold.

Paul Tudor Jones first reported a position in NGNE in Q3 2015 and held it in 3 quarters. The position peaked at $352K in Q4 2015. 34 funds tracked by Wall St. Rank hold NGNE as of Q2 2016.

  • Paul Tudor Jones reported no remaining Neurogene position as of Q2 2016 after selling out during the quarter.
  • Paul Tudor Jones sold 1,246 Neurogene shares in Q2 2016, an estimated $220K.
  • Paul Tudor Jones first reported a position in Neurogene in Q3 2015 and held it in 3 quarters.
  • Paul Tudor Jones's Neurogene position peaked at $352K in Q4 2015.
  • 34 funds tracked by Wall St. Rank held Neurogene as of Q2 2016.

Based on Tudor Investment Corp's 13F filing for Q2 2016, filed 15 Aug 2016.